In response to EGFR inhibition, cancer cells often rely on other RTKs for bypass signaling.32,33 Consistent with this finding, intracranial tumors showed increased phosphorylation of IGF-1R and PDGFRα after WSD-0922 and erlotinib treatment (Supplementary Table 4). The gene discussed is IGF1R; the disease is cancer.